Duchenne muscular dystrophy (DMD) is a genetic disorder produced by mutations in the dystrophin gene. Patients develop muscle weakness that progresses over years, producing severe impairment of the patient’s mobility and requiring help for all daily life activities. This clinical progression is the result of a continuous loss of muscle fibers and their substitution by fibrotic and adipose tissue. The persistent damage of muscles that occurs in muscular dystrophy exhausts the pool of satellite cells—the main protagonists of muscle regeneration—and enhances the proliferation of fibro-adipogenic progenitor cells. Several growth factors and cytokines have been related to the processes of muscle degeneration and regeneration. These growth factors include transforming growth factor β; IL-1β; IL-6; tumor necrosis factor α; and, more recently, platelet-derived growth factors (PDGFs).

The family of PDGFs participates in several biological functions, such as cell proliferation, migration, and differentiation. All PDGFs are secreted as dimers of disulfide polypeptide chains by platelets, monocytes, endothelial cells, and other cell types. There are five types of PDGF dimers: the homodimers PDGF-AA, -BB, -CC, and -DD and the heterodimer PDGF-AB. Once released, these factors have a paracrine effect on surrounding PDGF receptor.
(PDGFR)-positive cells. Mesenchyme-derived cells, such as satellite cells or pericytes, express PDGFR. The two PDGFR isoforms, α and β, each are capable of homo- or heterodimerization in the presence of PDGF. PDGF-AA and PDGF-BB homodimers, whereas PDGF-AA and PDGF-BB heterodimers, in vivo. Once activated, PDGFR acquires tyrosine kinase activity, triggering multiple downstream pathways, such as Ras/mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase/protein kinase B (Akt), phospholipase Cγ/protein kinase C, or STATs that finally regulate gene expression.

PDGFs play a crucial role in early developmental processes, such as the formation of the neural crest, the spread of cells into growing tubular structures (eg, vessels or brachial pouches), and the proliferation of tissue-specific stromal cells (eg, dermal or renal fibroblasts). In adult humans, increased PDGF signaling has been related to several diseases, examples being atherosclerosis, cancer, and fibrosis.

The role of PDGFs in normal or pathologic skeletal muscle is not completely understood. It is known that PDGF-AA and PDGF-BB are secreted by muscle fibers in DMD patients. There is evidence to support a profibrotic role of PDGF-AA in muscle dystrophies: i) perivascular PDGFRα fibro-adipogenic progenitor cells proliferate after a muscle injury; ii) skeletal muscles from knock-in mice with PDGFRα-activating mutations in which there is a constitutive expression of PDGFRα, showed increased fibrotic tissue; and iii) treatment of mdx mice in a murine model of DMD—with PDGFRα antagonists—reduces skeletal muscle fibrosis.

In contrast, the role of PDGF-BB in skeletal muscle has not been clarified. Endothelial cells in healthy muscle express PDGF-BB, acting as a ligand for PDGFRβ pericytes, which confer structural support to the vessel wall. The role of PDGF-BB after muscle damage is unknown. It has been reported that PDGF-BB influences the proliferation of satellite cells in several animal species. Based on this previous finding, some authors have suggested that PDGF-BB could be relevant in muscle regeneration in patients with muscle diseases, but this concept has not been demonstrated.

Our aim was to study the possible role of PDGF-BB in muscle regeneration through a series of in vitro and in vivo experiments.

Materials and Methods

Muscle Biopsy

Muscle biopsies were performed as part of the diagnostic process in patients who visited the Neuromuscular Disorders Unit at Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). We studied the expression of PDGF-BB in muscle biopsy samples from patients with genetically confirmed DMD (n = 5) and from patients undergoing orthopedic surgery but who were otherwise healthy (controls; n = 5). All participants signed an informed-consent form, and all of the procedures were in accordance with the principles set forth in the Declaration of Helsinki.

Immunofluorescence and Western Blot

Muscle samples were frozen in liquid nitrogen—cooled isopentane, and serial 7-mm sections were cut with a cryostat (Leica Microsystems, Wetzlar, Germany).

Cell cultures were washed three times with phosphate-buffered saline and fixed with 4% paraformaldehyde at 4°C for 10 minutes. Cells and tissue sections were processed for microscopic evaluation as previously described.

Primary antibodies used in the experiments were rabbit anti-CD56 (Abcam, Cambridge, UK), rabbit anti-PDGF-BB (Santa Cruz Biotechnology, Dallas, TX), mouse anti-human embryonic myosin heavy chain (Novocastra, Newcastle upon Tyne, UK), mouse anti-murine embryonic myosin heavy chain (Hydroma Bank, Iowa City, IA), rabbit anti-PDGFRβ (Cell Signaling Technology, Danvers, MA), mouse anti-CD4 (Dako North America, Carpinteria, CA), mouse anti-CD8 (Dako), mouse anti-CD68 (Dako), rabbit anti-collagen I (Abcam), rabbit anti-nerve/glial antigens 2 chondroitin sulfate proteoglycan (EMD Millpore, Billerica, MA), mouse anti-desmin (Novocastra), mouse anti-z-smooth muscle actin (Sigma-Aldrich, St. Louis, MO), mouse anti-paired box protein (Pax) 7 antibody (Hydroma Bank), rat anti-laminin (Abcam), and the lectin *Ulex europaeus* (Vector Laboratories, Burlingame, CA). Appropriate Alexa-conjugated secondary antibodies were used.

Western blot analysis of cell cultures was performed as previously described. We extracted proteins from the cell pellets with a buffer containing 125 mM Li2SO4, 4% SDS, 4 M urea, 5% mercaptoethanol, 1% glycercer, bromphenol blue 0.0002%, and protease inhibitor cocktail (Sigma-Aldrich). The antibodies used for Western blot analysis were mouse anti-phospho-STAT-1 and mouse anti—STAT-1 (Santa Cruz Biotechnology); rabbit anti-p44/42 MAPK (Erk1/2), rabbit anti—phospho-p44/42 MAPK (Erk1/2), rabbit anti—phospho-p44/42 MAPK (Erk1/2), rabbit anti-Akt, and mouse anti—phospho-Akt (Ser473) (Cell Signaling Technologies); rabbit anti—collagen I (Abcam); and mouse anti—glyceraldehyde-3-phosphate (Sigma-Aldrich).

Isolation of Satellite Cells from Human Muscle Biopsy Samples

Human satellite cells were isolated from the muscle biopsy samples of patients with DMD and controls (n = 3 per group) as previously described. Briefly, muscle biopsies were minced into 1- to 2-mm pieces, transferred onto collagen type I (Sigma-Aldrich) coated dishes, and incubated in proliferating medium at 37°C, 5% CO2, and 5% O2. Proliferating medium consisted of a mixture of Iscove...
Dulbecco’s modified Eagle’s medium and M-199 medium (both from Lonza, Verviers, Belgium), in a 3:1 ratio, supplemented with 15% fetal bovine serum (FBS; Lonza), 2 mmol/L L-glutamine (Lonza), 5 ng/mL basic fibroblast growth factor (PeproTech, Rocky Hill, NJ), and 1% penicillin–streptomycin (Lonza). After 5 to 7 days, cells started to sprout from the muscle explants. We isolated myoblasts using anti-CD56–coated microbeads (Miltenyi Biotec, Gladbach, Germany) and confirmed that the purity of the samples was >95% performing immunofluorescence (IF) with antibodies anti-CD56 (Becton, Dickinson and Company, BD Biosciences, San Jose, CA) and anti-desmin (Leica Biosystems, Newcastle, UK) (Supplemental Figure S1). All experiments performed with myoblasts were repeated with the cells isolated from all patients \((n = 3)\) and were replicated in triplicate.

Culture Studies: Myotubes and Wounding Assays

To obtain myotubes, human myoblasts were seeded at a density of 2500 cells/cm² using growth medium containing Dulbecco’s modified medium/M-199 (3:1), 1% glutamine, 15% FBS, and 1% penicillin–streptomycin. Once myoblasts were confluent, we substituted this medium with a differentiation medium containing 2% FBS.

Several membrane-wounding assays were used for damaging myotubes: i) incubation with 0.25 mmol/L SDS for 2 minutes, followed by two washes with Hanks’ balanced salt solution 1X (Lonza); ii) incubation with 5 μmol/L ionomycin (Sigma-Aldrich) for 5 minutes, followed by two washes with Hanks’ balanced salt solution 1X; and iii) incubation of plates with 50 mg of glass beads in Hanks’ balanced salt solution 1X medium (Sigma-Aldrich) on a shaker for 5 minutes.

After damage, myotubes were incubated with Hanks’ balanced salt solution 1X medium for 10, 20, and 30 minutes. We measured the concentration of PDGF-BB in the supernatants using enzyme-linked immunosorbent assay (Human PDGF-BB Quantikine enzyme-linked immunosorbent assay; R&D Systems, Minneapolis, MN) following the manufacturer’s instructions. To measure the concentration of creatine kinase, supernatants were concentrated using Centricon Plus filter devices with a 30-kDa molecular weight cutoff (EMD Millipore) according to the manufacturer’s protocol. The samples obtained were analyzed in the Biochemistry Laboratory at Hospital de la Santa Creu i Sant Pau using an architect ci16200 device (Abbott Laboratories, Abbott Park, IL).

Culture Studies: Transwell Assays

Myoblasts (40,000 cells in Opti-MEM I medium; Lonza) were deposited into Falcon insert (3-μm–diameter pores; Becton, Dickinson and Company, Franklin Lakes, NJ) and placed on top of a well containing PDGF-BB concentrations of 10, 50, and 100 ng/mL (R&D Systems); PDGF-BB incubated previously with blocking anti–PDGF-BB antibody (EMD Millipore) for 1 hour at 37°C; or anti–PDGF-BB antibody alone. The culture inserts were incubated at 37°C for 24 hours.

We counted the cells present in the lower well and in the membrane. Chemotaxis toward Opti-MEM I medium was considered as nonspecific. The cells present in the insert were fixed in ethanol 70% for 10 minutes and stained for 30 minutes with crystal violet (Sigma-Aldrich). After three washes with phosphate-buffered saline, filters were cut, mounted onto a slide, and observed with an Olympus microscope (Olympus, Center Valley, PA).

Proliferation and Differentiation Assays

To study the specific influence of PDGF-BB on cell proliferation, we plated myoblasts with a concentration of 3500 cells/cm² and cultured them in a basal medium that contained only 1% FBS. We added to the medium PDGF-BB (R&D Systems) at a concentration of 10 nmol/L. Fresh PDGF-BB was added to the medium every 24 hours for 6 days. In parallel we also analyzed cell proliferation on an FBS-enriched medium; we plated myoblasts with a concentration of 3500 cells/cm² and cultured them in proliferating medium with or without PDGF-BB at a concentration of 10 nmol/L. For studying the effect of nintedanib (kindly donated by Boehringer Ingelheim, Rhein, Germany), a tyrosine kinase inhibitor that blocks the PDGFR, it was added to the proliferation medium at a concentration of 500 nmol/L. For counting the cells, the cultures were trypsinized and cells were stained with Trypan Blue. Living cells were counted in a hemocytometer.

For studying differentiation, myotubes obtained from three different conditions were compared: control myotubes, myotubes obtained from a differentiation medium containing 10 ng/mL PDGF-BB, and myotubes obtained from a differentiation medium containing 50 ng/mL PDGF-BB. After 7 days in differentiation medium, cultures were fixed and we performed IF using antibodies against developmental myosin and DAPI for the nuclei. We obtained images of 10 areas randomly at 20× magnification from every culture condition with the microscope. Images were analyzed using Adobe Photoshop software version CS6 (Adobe Systems, San Jose, CA). We assessed the differentiation rate by counting the total number of nuclei present in developmental myosin-positive myotubes versus the total number of nuclei.

Analysis of Intracellular Pathways

For these experiments, myoblasts were cultured overnight with 1% FBS Dulbecco’s modified Eagle’s medium. The following day, cells were treated with 10 ng/mL PDGF-BB for 15 minutes and fixed. A group of cells were pretreated with the tyrosine kinase inhibitor nintedanib at a concentration of 500 nmol/L for 2 hours before PDGF-BB treatment.
RNA Extraction and Reverse Transcription

Total RNA from cells was isolated using TRIzol following the manufacturer’s instructions (InvitroGen, Carlsbad, CA) and stored at −80°C. RNA was reverse-transcribed from 1 μg of total RNA using the High-Capacity cDNA Reverse-Transcription Kit (Applied Biosystems, Foster City, CA).

qPCR

Real-time quantitative (qPCR) of cDNA obtained from cells and tissues was performed using TaqMan Universal PCR Master Mix and the 7900HT Fast Realtime PCR System (both from Applied Biosystems). mRNA-specific fluorescein amidite–labeled primers/probe were purchased from Applied Biosystems for detecting cDNA from the following genes: PDGFB (Hs00966522_m1), MYOD1 (Hs00159528_m1), GAPDH (Hs99999905_m1), and Pdgfb (Mm00440677_m1). All experiments were performed in triplicate. Relative quantification was performed using the comparative Ct method, and all results were compared with the control samples for each treatment after normalization to an endogenous control (glyceraldehyde-3-phosphate) using the Relative Quantification Manager 7900 HT Fast Real-Time PCR System software package version 2.4.1 (Applied Biosystems). Data in bar graphs are expressed as the means ± SD of three independent samples.

In Vivo Treatment with Notexin

To investigate whether acute damage in skeletal muscle could increase the expression of PDGF-BB, we treated 5-month-old C57 (control) and mdx mice (n = 21 per group) with a single i.m. injection of 50 μL of Notexin Np (Latoxan S.A.S., Portes-lès-Valence, France) in the tibialis anterior muscles. We obtained the muscles injected at 1 and 24 hours and 3, 7, 15, and 21 days after damage (all time points, n = 3) and compared them with those from nontreated animals (n = 3). We studied muscle structure using hematoxylin and eosin staining and analyzed the expression of PDGF-BB using IF. In parallel, we quantified PDGF mRNA levels after damage as described in qPCR.

In Vivo Treatment with Repeated Injections of PDGF-BB

We used 8-month-old mdx mice for the in vivo experiments. Four mice were treated with repeated i.m. injections of PDGF-BB. We injected 100 μL at 50 ng/mL concentration, two times per week for 1 month in both tibialis anterior muscles. In parallel, four mice were treated with repeated i.m. injections of 100 μL of saline solution (vehicle) using the same protocol. Four nontreated mdx mice were used as controls. After treatment, the animals were sacrificed, and both tibialis anterior muscles were isolated for histologic analysis.

Using an Olympus microscope at 20× magnification, we obtained images of five random areas from each muscle biopsy sample. Images were analyzed using Adobe Photoshop software (Adobe Systems). To estimate the number of satellite cells, we performed double IF with the antibodies anti-Pax7 and anti-laminin, adding DAPI to identify the nuclei of the cells and myofibers. We counted the total number of Pax7+ cells and the total number of cells using DAPI. Moreover, we counted the total number of myofibers. The number of satellite cells was expressed as the ratio of Pax7+ cells to the total number of DAPI cells. We also analyzed the ratio of Pax7+ cells to the total number of fibers. A cross-sectional area of muscle fibers was analyzed using ImageJ software version 1.49 (NIH, Bethesda, MD; http://imagej.nih.gov). To analyze inflammation in the muscles, we counted all F4/80+ cells present in the muscle sections. We expressed the result as the ratio of F4/80+ cells to the total number of DAPI nuclei. Finally we analyzed the collagen I area using ImageJ software.

Statistical Analysis

We used the t-test to compare quantitative measures between samples, and analysis of variance to study repeated measures. Statistical significance was obtained at P < 0.05. Statistical studies were performed with IBM SPSS Statistics software version 21 (IBM, Armonk, NY), and graphics were developed using DataGraph software version 4.0 (Visual Data Tools; http://www.visualdatatools.com/DataGraph).

Results

PDGF-BB Expression in Control Patients and in Patients with DMD

In muscle biopsy samples obtained from controls (n = 5), we observed that PDGF-BB was expressed in the vessel wall of capillaries but not in muscle fibers (Figure 1, A and C). Conversely, in muscle biopsy samples from DMD patients, PDGF-BB was expressed in vessels but also in the sarcoplasm of many muscle fibers (Figure 1, B and D) and in inflammatory infiltrates (Figure 1, F–N). We observed that both CD8+ T cells and CD4+ T cells and also CD68+ cells (macrophages) expressed PDGF-BB. Satellite cells did not express PDGF-BB in vivo (Supplemental Figure S2). qPCR showed an increased expression of PDGF-BB in muscle biopsy samples from patients with DMD compared with those from controls (Figure 1E).

PDGF-BB Is Expressed in Regenerating Fibers and Necrotic Fibers

We observed that, in many cases, several PDGF-BB+ muscle fibers were pale on hematoxylin and eosin staining, suggesting that the fibers were necrotic (Figure 2, A and B).
However, we also observed that many PDGF-BB fibers expressed developmental myosin, a known marker of regenerative fibers (Figure 2, C and D). To confirm this observation in vitro, we cultured myoblasts from controls and patients with DMD and differentiated them into myotubes. Using IF, we observed that myotubes expressed higher levels of PDGF-BB than did myoblasts (Figure 2, E–J). A significant increase in mRNA levels of PDGFB in

Figure 1   Platelet-derived growth factor (PDGF)-BB expression in healthy and pathologic muscle. The expression of PDGF-BB was studied using immunohistochemistry analysis in biopsy samples from healthy muscle (A and C) and in Duchenne dystrophic muscle (DMD; B and D). In healthy muscle, PDGF-BB was expressed in the vessel wall (boxed region from A is detailed in C). In muscle from DMD patients, PDGF-BB was also expressed in muscle fibers (boxed region from B is detailed in D). The expression of PDGF-BB in inflammatory infiltrates in muscle biopsy samples from patients with DMD was detected: CD4⁺ T cells (F–H), CD8⁺ T cells (I–K), and CD68⁺ macrophages (L–N); real-time quantitative PCR performed on cDNA obtained from control (Ctrl) muscle and from muscle of patients with DMD shows increased expression of PDGFB in DMD muscle biopsy samples (E). Data are expressed as means ± SD (E). n = 4 per group (E). **P < 0.01 (t-test). Scale bars: 200 μm (A and B); 50 μm (F–N).
myotubes compared with those in undifferentiated myoblasts was observed using qPCR ($n = 3$; $P = 0.045$; $t$-test) (Figure 2G).

To investigate whether an injury can release PDGF-BB from inside muscle fibers, we induced a chemical injury (SDS and ionomycin) or a physical injury (glass beads) in myotubes obtained from the myoblasts of controls and DMD patients ($n = 3$ per group). We subsequently analyzed PDGF-BB concentrations in culture supernatants using enzyme-linked immunosorbent assay. We observed that the concentration of PDGF-BB was increased progressively in all samples after damage (Figure 2K). The

Figure 2  Regenerating and necrotic myofibers and myotubes express platelet-derived growth factor (PDGF)-BB. A–D: PDGF-BB is expressed in vivo by necrotic fibers (A and B) and by regenerative developmental myosin (MyoDev)-positive fibers (C and D). PDGF-BB is more highly expressed in myotubes compared with undifferentiated myoblasts. E–J: Double immunofluorescence shows expression of PDGF-BB by multinucleated myotubes (H–J) but not in nondifferentiated myoblasts (E and F) (the boxed region from I is detailed in J). Relative quantification of PDGFB mRNA in healthy skeletal muscle cultures shows a 33-fold increase in PDGFB in myotubes compared with controls (G). K: Expression of PDGF-BB by enzyme-linked immunosorbent assay in supernatants of myotubes obtained from DMD patients and controls after the induction of a chemical (SDS and ionomycin) or a physical (glass beads) injury. L: Quantification of creatine kinase levels in supernatants of control damaged myotubes 10 and 30 minutes and 24 and 48 minutes after damage. M: Relative quantification of PDGFB mRNA in damaged myotube cultures obtained from control patients. Data are expressed as means ± SD (G, K, and M). $n = 5$ (G, K, and L); $n = 3$ DMD patients (K). *$P < 0.05$, **$P < 0.01$. Scale bars: 50 μm (A–D); 200 μm (E, F, H, and J); 100 μm (J). He-Eos, hematoxylin and eosin.
increase was significantly greater ($P < 0.05$; analysis of variance) and occurred earlier in the myotubes from DMD patients than in those from controls. Creatine kinase level in the supernatant of cultures was increased just after damage and returned to normal value at 48 hours after the initial lesion (Figure 2L). PDGFB mRNA, however, remained unchanged despite the damage (Figure 2M).

**PDGFRβ Is Expressed in Muscle Fibers, Pericytes, and Satellite Cells in Muscle Biopsy Samples from Patients with Muscular Dystrophies**

It is well known that PDGF-BB has a paracrine effect on PDGFRβ$^+$ cells. For this reason, we analyzed which cells expressed PDGFRβ in muscle biopsy samples from controls and DMD patients (n = 5 per group). PDGFRβ was expressed in vessel wall (Figure 3A) in controls. We identified PDGRβ in vessel-associated cells (Figure 3, B–D) expressing neural/glial antigen 2 (Figure 3, E–H) and smooth muscle actin (Figure 3, I–L). These cells might be pericytes, as they have been previously shown/demonstrated to express PDGFRβ. In patients with DMD, we found that PDGFRβ was expressed in vessels and also in the sarcolemma (Figure 3, M–O) and sarcoplasm (Figure 3, M–O) of some muscle fibers (Figure 3B). Satellite cells expressing CD56$^+$ were also positive for PDGFRβ (Figure 3, P–V). Myoblasts isolated from muscle biopsy samples expressed PDGFRβ in culture (Supplemental Figure S2), supporting the results obtained in vivo. CD4 and CD68 cells did not express PDGFRβ in vivo in muscle biopsy samples from patients with DMD (Supplemental Figure S3).

**Injection of Notexin into Skeletal Muscle of Control Mice Increases Expression of Pdgf-BB**

Acute damage after injection of notexin or cardiotoxin in skeletal muscle has been widely studied. In wild-type muscle, we observed widespread necrotic fibers 24 hours after injection (Figure 4, A and B). After 3 days, inflammatory infiltrates coexisted with incipient regenerating fibers (Figure 4C), which were more prominent at 7 days (Figure 4D). At 21 days, muscle regeneration was complete (Figure 4E). Sequence of muscle damage in mdx mice was similar, although there were some differences. Inflammatory infiltrates appeared earlier; at 24 hours, groups of necrotic fibers were undergoing phagocytosis (Figure 4, K and L). At 3 days, inflammatory cells coexisted with regenerating fibers (Figure 4M), which were predominant at 7 days (Figure 4N). Pdgf-BB expression in skeletal muscle was clearly increased after damage (Figure 4, F–J). Muscle fibers [both necrotic (Figure 4, H and Q) regenerant (Figure 4, I and R)] and inflammatory infiltrates produced Pdgf-BB. In control muscles, Pdgfb progressively increased, peaking at 3 days, which coincided with maximum inflammatory infiltration and with the start of the regeneration process (Figure 4U). Then, Pdgfb levels decreased progressively and returned to normal values at 21 days, when skeletal muscle regeneration was completed. In mdx mice, Pdgfb levels started increasing earlier (Figure 4U). We observed a first peak at 24 days, which coincided with the inflammatory infiltration. The high levels persisted at 3 days, when many incipient regenerating fibers could be detected, and then it progressively decreased, returning to normal levels at 21 days after damage.

**Influence of PDGF-BB on Myoblast Proliferation, Chemotaxis, and Differentiation**

We analyzed the effects of PDGF-BB on proliferation, migration, and differentiation of myoblasts isolated from human skeletal muscles. PDGF-BB significantly increased the proliferation of myoblasts after 4 and 6 days of treatment at concentrations of 10 ng/mL both in proliferation medium enriched with FBS (n = 3; $P = 0.03$; analysis of variance) (Figure 5A) and in more demanding culture conditions, such as a medium containing only 1% FBS and PDGF-BB ($P = 0.02$; analysis of variance) (Figure 5B). Nintedanib completely reversed the effect of PDGF-BB on myoblast proliferation (Figure 5, A and B). PDGF-BB did not have any effect on the differentiation of myoblasts to myotubes. We detected a variation in neither the differentiation ratio nor in the number of nuclei per myotube after adding 10 or 50 ng/mL PDGF-BB to the culture medium (Figure 5, C and D and F–H). Moreover, we did not observe differences in the mRNA levels of MYOD1 in myoblasts treated with 10 ng/mL PDGF-BB for 24 hours (Figure 5E). PDGF-BB produced a statistically significant increase in the chemotaxis of myoblasts in a dose-dependent manner ($P < 0.05$; t-test) (Figure 5I).

To explore the molecular basis of the biological effect produced by PDGF-BB on myoblasts, we studied the intracellular pathways activated by PDGF-BB after 15 minutes of treatment. We observed that 10 ng/mL of PDGF-BB significantly increased phosphorylated (p)-AKT levels in myoblasts ($P = 0.001$; t-test), whereas it had no effect on the phosphorylation of ERK1/2 or STAT-1 (Figure 5, J and K). Nintedanib blocked phosphorylation of Akt after treatment with PDGF-BB.

**Treatment of mdx Mice with PDGF-BB Enhances Muscle Regeneration**

We studied whether the treatment of mdx mice with i.m. injections of PDGF-BB would induce an expansion of the satellite cell pool in vivo as a proof of principle. We treated four mdx mice twice a week with i.m. injections of PDGF-BB. After 1 month of treatment, muscles from PDGF-BB–treated animals were clearly different from those of vehicle-treated mice. We observed a clear reduction in inflammatory infiltrates (Figure 6, A–D and M–P) in muscles treated with PDGF-BB compared with those in...
controls (nontreated) and vehicle-treated muscles. The population of Pax7$^+$ satellite cells was increased significantly in muscle from PDGF-BB–treated mdx mice compared with those from nontreated and vehicle-treated mdx mice ($P = 0.03$; $t$-test) (Figure 6, E–H). The increase in the population of satellite cells was associated with an increase in the number of regenerative muscle fibers (11.8% in PDGF-BB–treated muscle versus 6.93% in vehicle-treated muscle) ($P = 0.04$; $t$-test) (Figure 6, I–L) and a reduction in the cross-sectional area of the fibers ($P = 0.03$; $t$-test) (Figure 5D). Collagen I expression was not influenced by injection of PDGF-BB;

Figure 3  Platelet-derived growth factor receptor (PDGFR)-β expression in control and dystrophic muscle biopsy samples. A–D: PDGFR-β is expressed by perivascular cells in control muscle biopsy samples. Arrows in B–D show a PDGFR-β$^+$ cell (C) close to a Ulex$^-$ capillary (B). E–O: PDGFR-β$^+$ cells co-express neural/glial antigen 2 (E–H) and smooth muscle actin (I–L), probably being pericytes. In Duchenne muscle biopsy samples, sarcolemma and sarcoplasm in some muscle fibers were also stained (M–O). Arrows in M–O show sarcolemma of a muscle fiber stained by laminin and PDGFR-β$^+$. Asterisks in M–O show sarcoplasm of a muscle fiber stained with PDGFR-β$^-$. P–V: Satellite cells co-express CD56 and PDGFRβ in Duchenne muscle dystrophy patients. Arrowheads in P–R show two satellite cells co-expressing CD56 and PDGFR-β$^+$. Scale bars: 50 μm (A–D); 200 μm (E–G, I, K, and M–U); 100 μm (J).
we did not detect significant changes in the area covered by collagen I in muscle tissue and we did not observe differences in the expression of collagen I using Western blot analysis (Supplemental Figure S4).

Discussion
Our study demonstrates that PDGF-BB may influence the process of muscle regeneration in patients with DMD. We
base our conclusion on the following key results: i) PDGF-BB was secreted by necrotic and regenerative fibers and by inflammatory infiltrates in muscle biopsy samples from patients with DMD; ii) myotubes expressed higher levels of PDGF-BB than did undifferentiated myoblasts in culture; iii) secretion of PDGF-BB from damaged mature myotubes after chemical and physical damage was detected; iv) PDGF-BB expression in notexin-injured muscle was clearly increased, coinciding with infiltration of inflammatory cells and muscle regeneration; v) PDGF-BB activated myoblasts, inducing their proliferation and migration; and vi) treatment of mdx mice with i.m. injections of PDGF-BB increased the population of satellite cells and the number of regenerative fibers.

We previously reported that the population of satellite cells increases in biopsy samples from patients with DMD and Becker muscle dystrophy. To determine which factors could influence this increase, we studied PDGFs because they have been related to the proliferation of several mesenchymal cells. We found that PDGF-BB was the member of the PDGF family that displayed the highest level of expression in muscle biopsy samples from DMD patients (data not shown). Zhao et al had already reported an increased expression of PDGF-BB in muscle fibers from DMD patients, although their results were based only in IF
and were not confirmed using Western blot analysis, qPCR, or in vitro studies as we performed in our study. We observed that PDGF-BB+ muscle fibers expressed markers of muscle regeneration, such as developmental myosin, suggesting that PDGF-BB could have an effect in the process of muscle regeneration in vivo. Our in vitro results supported this hypothesis: PDGFB increased during differentiation from myoblast to myotubes. Moreover, we have observed that PDGF-BB is quickly released by myotubes after chemical or physical damage and then can activate surrounding cells. We have also observed that many necrotic fibers expressed PDGF-BB in vivo, suggesting that PDGF-BB could function as a regeneration signal released by fibers after injury, as described in other tissues such as bone or liver. The results of our neotxin-induced muscle damage support this fact. PDGF-BB expression was clearly increased after acute damage, coinciding with the inflammatory infiltrate and the start of the regeneration process.

![Figure 6](https://example.com/figure6.png)

**Figure 6** Treatment of mdx mice with platelet-derived growth factor (PDGF)-BB enhances muscle regeneration and proliferation of satellite cells and pericytes. A–C: Muscle from mdx mice treated with an i.m. injection of PDGF-BB show significant histologic changes compared with vehicle-treated muscle. More regenerative fibers that are smaller, and fewer inflammatory cells, are observed. D: Cross-sectional area of muscle fibers is smaller in PDGF-BB–treated muscles. E–H: The number of developmental myosin (DevMyo)–expressing fibers is significantly increased in PDGF-BB–treated muscles compared with nontreated (control) muscles and vehicle–treated muscles. I–L: The population of inflammatory cells invading muscles treated with PDGF-BB decreases compared with that in vehicle–treated muscles. M–P: The population of paired box 7 protein (Pax7) satellite cells significantly increases in PDGF-BB–treated muscles compared with that in nontreated muscles and vehicle–treated muscles. Q–V: Most of the Pax7+ cells also express PDGF receptor (PDGFR)–J. Data are expressed as means ± SD (D, H, L, and P). n = 4 per group (D, H, L, and P). *P < 0.05; **P < 0.01. Scale bars = 50 μm. Original magnification: ×400 (T–W). Lam, laminin.
mimicking that has been described with other well-known mitotic factors, such as hepatic growth factor, fibroblast growth factor, and insulin growth factor. PDGFs act primarily as paracrine growth factors, so it is likely that the release of PDGF-BB from regenerating muscle fibers has an effect on surrounding cells expressing PDGFRβ, such as pericytes or satellite cells.

Satellite cells in a quiescent state are located beneath the basal lamina of healthy muscle fibers. After damage, satellite cells are activated and then proliferate and differentiate into myoblasts, fusing to injured muscle fibers and contributing to muscle regeneration. Satellite cells are activated in response to several signals from regenerative microenvironment, such as adhesion molecules, necrotic cues released from damaged fibers, and growth factors and cytokines produced by neighboring cells. Several growth factors, including hepatic growth factor, fibroblast growth factor, IL-1, IL-6, insulin growth factor, influence the proliferation of satellite cells. It is well known that PDGFs are potent mitogens for a variety of mesenchymal cell types. It has been previously described that PDGF-BB enhances the proliferation of myoblasts obtained from several animal species, such as the mouse, rat, and chicken. We have observed a homologous effect in human myoblasts. The fact that this process seems to be conserved along the vertebrate lineage, supports an important role of PDGF-BB in proliferation of satellite cells. Phosphorylation of PDGFRβ activates several well-characterized intracellular signaling pathways such as MAPK/ERK, phosphoinositide 3-kinase/Akt, and protein kinase C, which are known to be involved in multiple cellular responses. Some of these pathways, including Akt, ERK1/2, and STATs, have also been involved in the proliferation of myoblasts. Here, we observed that PDGF-BB enhanced Akt phosphorylation, but in contrast it had no effect on the MAPK/ERK or Janus kinase (JAK)/STAT pathway.

To differentiate and fuse into damaged fibers, proliferating myoblasts must migrate and establish stable cell contact. Cell migration is therefore essential for adult muscle repair. The effect of several factors on myoblast migration has been previously studied, yet the process of cell migration is not completely understood. PDGF-BB has a well-characterized role in the migration of many different mesenchymal cells during organogenesis and in disease. In the case of skeletal muscle, PDGF-BB orchestrates the migration of murine embryonic myoblasts from somites toward the limb. Hereby we have shown that PDGF-BB enhanced satellite cell migration in vitro in a dose-dependent manner. Based on our observations it is tempting to hypothesize that PDGF-BB released by regenerating muscle fibers activates satellite cell proliferation and migration of these cells toward muscle fibers.

We have observed that PDGF-BB does not have any effect on the differentiation of myoblasts in vitro. It has been previously reported that PDGF-BB delayed and decreased the differentiation process of myoblasts in vitro. However, Jin et al. reported that PDGFR mRNA rapidly decreased once differentiation of rat myoblasts started, suggesting that PDGF-BB acts only on proliferating myoblasts and not on myoblasts undergoing differentiation in vitro. Our results support this hypothesis; we did not observe any effect in the differentiation index of myoblasts in vitro. In contrast, we observed that treatment of mdx mice with repeated i.m. injections of PDGF-BB increased the number of satellite cells, confirming the positive effect on proliferation of PDGF-BB. Consequently, the number of regenerative fibers increased, suggesting that PDGF-BB did not decrease the ability of satellite cells to differentiate in vivo.

We confirmed our in vitro results with an in vivo model of DMD as a proof-of-principle approach. We observed that the treatment of mdx mice with repeated i.m. injections of PDGF-BB produced increases in the population of satellite cells and in the number of regenerative fibers. Inflammatory infiltrates were also reduced and muscle tissue fibrosis did not increase. These observations demonstrate that PDGF-BB could promote muscle regeneration in a murine model of DMD. Muscle degeneration in patients with muscular dystrophies is a complex process produced by the confluence of different factors. On one hand there is an expansion of fibrotic tissue; on the other hand there is an impairment of the regenerative process of skeletal muscle. It is well known that pro-inflammatory invading macrophages continuously release profibrotic growth factors, such as transforming growth factor β and PDGF-AA, which activates PDGFRα, fibro-adipogenic progenitor cells, enhancing the expansion of fibrotic tissue. Tyrosine kinase inhibitor drugs, such as imatinib or crenolanib, block phosphorylation of several cell receptors, including PDGFRs. These drugs have shown effectiveness in reducing fibrosis and accordingly improving muscle function. Based on our results, we could hypothesize that tyrosine kinase inhibitors may impair muscle regeneration by blocking the effects of PDGF-BB on satellite cells. This concept has not been studied in any of the reports published. However, satellite cell proliferation does not depend only on the effects of PDGF-BB; other growth factors such as IL-6, hepatic growth factor, and stromal cell—derived factor 1 influence it. None of them are blocked by tyrosine kinase inhibitor; therefore, expansion of satellite cells in a tyrosine kinase—treated animal model may not be compromised. It has also been suggested that damaged muscle fibers could express factors that promote muscle regeneration. Hereby we present data supporting a role of PDGF-BB released by muscle fibers as a pro-regenerative factor in patients with DMD.

In conclusion, our results support the hypothesis that PDGF-BB would be released by muscle fibers to promote muscle regeneration in dystrophic muscles by activating the proliferation and migration of satellite cells to injured muscle.
muscle fibers. Based on our results, we propose that treatment with agonists of PDGFRβ in animal models of muscular dystrophy may result in an improvement in muscle regeneration and, consequently, a reduction in muscle loss.

Acknowledgments

We thank Miquel Navas for technical support with the experiments and Luis Querol, Sonia Segovia, Juan Jesus Vilchez, Carolyn Newey, Sergi Martinez-Ramirez, and Sara DeGregorio for editorial comments.

P.P.-J., N.d.L., and X.S.-C. designed and performed experiments, collected and analyzed data, and wrote the manuscript; E.G. and J.D.-M. designed the experiments, analyzed data, wrote the manuscript, and provided funding; C.S.-R. designed the experiments, collected and analyzed data, wrote the manuscript; I.I. performed experiments, wrote the manuscript, and provided funding; E.G. and J.D.-M. designed the experiments, and Luis Querol, Sonia Segovia, Juan Jesus Vilchez, Carolyn Newey, Sergi Martinez-Ramirez, and Sara DeGregorio for editorial comments.

Supplemental material for this article can be found at http://dx.doi.org/10.1016/j.ajpath.2017.04.011.

References


31. Nazari M, Ni NC, Ludke A, Li SH, Guo J, Weisel RD, Li RK: Mast cells promote proliferation and migration and inhibit differentiation of mesenchymal stem cells through PDGF. J Mol Cell Cardiol 2016, 94:32–42


52. Burks TN, Cohn RD: Role of TGF-beta signaling in inherited and acquired myopathies. Skelet Muscle 2011, 1:19

